Alnylam Pharmace. sell Biotechhunter
Summary
This prediction ended on 11.08.20 with a price of €116.52. With a performance of -1.30%, the SELL prediction for Alnylam Pharmace. by Biotechhunter was down slightly. Biotechhunter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -0.144% | -0.144% | 24.910% | 55.524% |
| iShares Core DAX® | -0.437% | -5.315% | 1.438% | 57.846% |
| iShares Nasdaq 100 | -0.194% | 3.078% | 18.683% | 84.823% |
| iShares Nikkei 225® | -0.951% | -5.884% | 27.860% | 54.805% |
| iShares S&P 500 | -0.420% | 0.922% | 13.173% | 64.029% |
Comments by Biotechhunter for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.


